Treating lupus kidney inflammation with or without extra steroid tablets
Part of Immune system & allergy, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This trial tests whether adding standard oral steroid tablets to mycophenolate helps lupus nephritis (inflammation of the kidneys) more than using obinutuzumab plus mycophenolate, without extra oral steroids. It may help find a treatment plan that controls active kidney disease while changing how much steroid is used.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 14–17 or an adult
- You have active lupus nephritis confirmed by a recent kidney biopsy (within 8 weeks)
- Your urine protein level is high (urine protein-to-creatinine ratio 0.5 or higher) in the last 14 days
- Your medical team says you can safely receive IV steroid, mycophenolate, oral steroid, or obinutuzumab
- You must be able to make your own health decisions (or have a legal guardian) and agree to contraception if using mycophenolate
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a medication called obinutuzumab for people with lupus-related kidney disease, specifically a type called pure membranous nephropathy. The goal is to see if it helps reduce protein leaking into the urine and improves kidney health.
This trial tests whether adding the drug obinutuzumab to standard therapy (mycophenolate and steroids) helps control lupus-related kidney inflammation better than standard therapy alone. It might reduce kidney damage and improve outcomes for people with active lupus nephritis.
This trial looks at whether people with proliferative lupus nephritis can use less steroid medicine while still controlling kidney inflammation. It may help reduce steroid side effects, while testing a carefully monitored treatment plan.
This Phase 2 study tests obinutuzumab, a targeted antibody medicine, in teens with active lupus nephritis (inflammation in the kidney). It looks at whether it helps kidney disease and is safe, including how the body handles the drug.
This study tests whether adding LUPKYNIS (a drug that protects the kidney) to one of three immune-system medications helps people with lupus nephritis (lupus affecting the kidneys). The goal is to reduce protein in urine and protect kidney function.
This trial tests two biologic drugs (belimumab or telitacicept) compared to a standard treatment (mycophenolate mofetil) for people with active lupus nephritis. The goal is to see if biologics work better at controlling kidney inflammation over 6 months.
Hear when a new Lupus Nephritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.